Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 63


Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms.

De Stefano V, Carobbio A, Di Lazzaro V, Guglielmelli P, Iurlo A, Finazzi MC, Rumi E, Cervantes F, Elli EM, Randi ML, Griesshammer M, Palandri F, Bonifacio M, Hernandez-Boluda JC, Cacciola R, Miroslava P, Carli G, Beggiato E, Ellis MH, Musolino C, Gaidano G, Rapezzi D, Tieghi A, Lunghi F, Loscocco GG, Cattaneo D, Cortelezzi A, Betti S, Rossi E, Finazzi G, Censori B, Cazzola M, Bellini M, Arellano-Rodrigo E, Bertozzi I, Sadjadian P, Vianelli N, Scaffidi L, Gomez M, Cacciola E, Vannucchi AM, Barbui T.

Blood Cancer J. 2018 Feb 28;8(3):25. doi: 10.1038/s41408-018-0048-9.


Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: A systematic review.

Marchetti M, Carobbio A, Capitoni E, Barbui T.

Am J Hematol. 2018 Jan 27. doi: 10.1002/ajh.25049. [Epub ahead of print]


Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data.

Ghirardi A, Carobbio A, Masciulli A, Barbui T.

Blood Cancer J. 2018 Jan 16;8(1):5. doi: 10.1038/s41408-017-0038-3. No abstract available.


Innovative haematological parameters for early diagnosis of sepsis in adult patients admitted in intensive care unit.

Buoro S, Manenti B, Seghezzi M, Dominoni P, Barbui T, Ghirardi A, Carobbio A, Marchesi G, Riva I, Nasi A, Ottomano C, Lippi G.

J Clin Pathol. 2018 Apr;71(4):330-335. doi: 10.1136/jclinpath-2017-204643. Epub 2017 Aug 20.


A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study.

Barbui T, Vannucchi AM, Finazzi G, Finazzi MC, Masciulli A, Carobbio A, Ghirardi A, Tognoni G.

Am J Hematol. 2017 Nov;92(11):1131-1136. doi: 10.1002/ajh.24851. Epub 2017 Jul 29.


Robotic Transnasal Endoscopic Skull Base Surgery: Systematic Review of the Literature and Report of a Novel Prototype for a Hybrid System (Brescia Endoscope Assistant Robotic Holder).

Bolzoni Villaret A, Doglietto F, Carobbio A, Schreiber A, Panni C, Piantoni E, Guida G, Fontanella MM, Nicolai P, Cassinis R.

World Neurosurg. 2017 Sep;105:875-883. doi: 10.1016/j.wneu.2017.06.089. Epub 2017 Jun 20.


Echocardiographic outflow pump ramp test in centrifugal-flow left ventricular assist device.

Iacovoni A, Vittori C, Fontana A, Carobbio A, Fino C, D'Elia E, Terzi A, Senni M.

Int J Artif Organs. 2017 Apr 18:0. doi: 10.5301/ijao.5000573. [Epub ahead of print]


No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials.

Barbui T, Carobbio A, Ghirardi A, Masciulli A, Rambaldi A, Vannucchi AM.

Haematologica. 2017 Jun;102(6):e219-e221. doi: 10.3324/haematol.2017.165126. Epub 2017 Mar 2. No abstract available.


Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera.

Lussana F, Carobbio A, Salmoiraghi S, Guglielmelli P, Vannucchi AM, Bottazzi B, Leone R, Mantovani A, Barbui T, Rambaldi A.

J Hematol Oncol. 2017 Feb 22;10(1):54. doi: 10.1186/s13045-017-0425-z.


Diagnostic impact of the 2016 revised who criteria for polycythemia vera.

Barbui T, Thiele J, Gisslinger H, Carobbio A, Vannucchi AM, Tefferi A.

Am J Hematol. 2017 May;92(5):417-419. doi: 10.1002/ajh.24684. Epub 2017 Mar 4. No abstract available.


ACE inhibitors and cytoreductive therapy in polycythemia vera.

Barbui T, Masciulli A, Ghirardi A, Carobbio A.

Blood. 2017 Mar 2;129(9):1226-1227. doi: 10.1182/blood-2016-11-752600. Epub 2016 Dec 27. No abstract available.


Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence: The AIRTRIP Randomized Clinical Trial.

Brucato A, Imazio M, Gattorno M, Lazaros G, Maestroni S, Carraro M, Finetti M, Cumetti D, Carobbio A, Ruperto N, Marcolongo R, Lorini M, Rimini A, Valenti A, Erre GL, Sormani MP, Belli R, Gaita F, Martini A.

JAMA. 2016 Nov 8;316(18):1906-1912. doi: 10.1001/jama.2016.15826.


Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients.

De Stefano V, Vannucchi AM, Ruggeri M, Cervantes F, Alvarez-Larrán A, Iurlo A, Randi ML, Pieri L, Rossi E, Guglielmelli P, Betti S, Elli E, Finazzi MC, Finazzi G, Zetterberg E, Vianelli N, Gaidano G, Nichele I, Cattaneo D, Palova M, Ellis MH, Cacciola E, Tieghi A, Hernandez-Boluda JC, Pungolino E, Specchia G, Rapezzi D, Forcina A, Musolino C, Carobbio A, Griesshammer M, Barbui T.

Blood Cancer J. 2016 Nov 4;6(11):e493. doi: 10.1038/bcj.2016.103.


The effect of arterial hypertension on thrombosis in low-risk polycythemia vera.

Barbui T, Vannucchi AM, Carobbio A, Rumi E, Finazzi G, Gisslinger H, Ruggeri M, Randi ML, Cazzola M, Rambaldi A, Gisslinger B, Pieri L, Thiele J, Pardanani A, Tefferi A.

Am J Hematol. 2017 Jan;92(1):E5-E6. doi: 10.1002/ajh.24583. No abstract available.


High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists.

De Stefano V, Ruggeri M, Cervantes F, Alvarez-Larrán A, Iurlo A, Randi ML, Elli E, Finazzi MC, Finazzi G, Zetterberg E, Vianelli N, Gaidano G, Rossi E, Betti S, Nichele I, Cattaneo D, Palova M, Ellis MH, Cacciola R, Tieghi A, Hernandez-Boluda JC, Pungolino E, Specchia G, Rapezzi D, Forcina A, Musolino C, Carobbio A, Griesshammer M, Sant'Antonio E, Vannucchi AM, Barbui T.

Leukemia. 2016 Oct;30(10):2032-2038. doi: 10.1038/leu.2016.85. Epub 2016 Apr 26.


Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia.

Barbui T, Vannucchi AM, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Gisslinger H, Finazzi G, Carobbio A, Thiele J, Passamonti F, Falcone C, Tefferi A.

Blood Cancer J. 2015 Nov 27;5:e369. doi: 10.1038/bcj.2015.94. No abstract available.


The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600.

Massi D, Brusa D, Merelli B, Falcone C, Xue G, Carobbio A, Nassini R, Baroni G, Tamborini E, Cattaneo L, Audrito V, Deaglio S, Mandalà M.

Ann Oncol. 2015 Sep;26(9):1980-7. doi: 10.1093/annonc/mdv255. Epub 2015 Jun 2.


Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis.

Barbui T, Vannucchi AM, Carobbio A, Thiele J, Rumi E, Gisslinger H, Rodeghiero F, Randi ML, Rambaldi A, Pieri L, Pardanani A, Passamonti F, Finazzi G, Tefferi A.

Am J Hematol. 2015 May;90(5):434-7. doi: 10.1002/ajh.23970. Epub 2015 Feb 27.


CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis.

Finazzi MC, Carobbio A, Cervantes F, Isola IM, Vannucchi AM, Guglielmelli P, Rambaldi A, Finazzi G, Barosi G, Barbui T.

Leukemia. 2015 May;29(5):1209-10. doi: 10.1038/leu.2014.343. Epub 2014 Dec 8. No abstract available.


The rate of transformation from JAK2-mutated ET to PV is influenced by an accurate WHO-defined clinico-morphological diagnosis.

Barbui T, Thiele J, Carobbio A, Vannucchi AM, Tefferi A.

Leukemia. 2015 Apr;29(4):992-3. doi: 10.1038/leu.2014.328. Epub 2014 Nov 26. No abstract available.


Supplemental Content

Loading ...
Support Center